These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24830786)

  • 21. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
    Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.
    Kiyota M; Kuroda J; Yamamoto-Sugitani M; Shimura Y; Nakayama R; Nagoshi H; Mizutani S; Chinen Y; Sasaki N; Sakamoto N; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
    Apoptosis; 2013 Nov; 18(11):1437-1446. PubMed ID: 23851982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia.
    Shao S; Li S; Qin Y; Wang X; Yang Y; Bai H; Zhou L; Zhao C; Wang C
    Int J Oncol; 2014 May; 44(5):1661-8. PubMed ID: 24585095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells.
    Bernusso VA; Machado-Neto JA; Pericole FV; Vieira KP; Duarte AS; Traina F; Hansen MD; Olalla Saad ST; Barcellos KS
    Biochim Biophys Acta; 2015 Feb; 1853(2):388-95. PubMed ID: 25450971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia.
    Xia DY; Liu L; Hao MW; Liu Q; Chen RA; Liang YM
    Braz J Med Biol Res; 2014 Dec; 47(12):1096-101. PubMed ID: 25387678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.
    Bu Q; Cui L; Li J; Du X; Zou W; Ding K; Pan J
    Cancer Biol Ther; 2014 Jul; 15(7):951-62. PubMed ID: 24759597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
    Wei YL; Liang Y; Xu L; Zhao XY
    Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition.
    Niu CC; Zhao C; Zhang XL; Pan J; Zhao C; Wu WR; Li ZQ; Liu T; Yang Z; Si WK
    Leuk Res; 2013 Nov; 37(11):1532-7. PubMed ID: 23972517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
    Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
    Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
    Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK
    Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells.
    Hazlehurst LA; Argilagos RF; Dalton WS
    Br J Haematol; 2007 Jan; 136(2):269-75. PubMed ID: 17233818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo.
    Wei YL; Xu L; Liang Y; Xu XH; Zhao XY
    Acta Pharmacol Sin; 2009 Apr; 30(4):451-7. PubMed ID: 19270722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment.
    Zhang H; Chang G; Wang J; Lin Y; Ma L; Pang T
    Leuk Res; 2013 Nov; 37(11):1583-91. PubMed ID: 24125838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
    Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A
    Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib.
    Augis V; Airiau K; Josselin M; Turcq B; Mahon FX; Belloc F
    PLoS One; 2013; 8(11):e78582. PubMed ID: 24223824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Increasing sensitivity of leukemia cells to imatinib by inhibiting NHE1 and p38MAPK signaling pathway].
    Hu RH; Jin WN; Chang GQ; Lin YN; Wang J; Ru YX; Li QH; Pang TX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1341-5. PubMed ID: 23257429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release.
    Ishii Y; Nhiayi MK; Tse E; Cheng J; Massimino M; Durden DL; Vigneri P; Wang JY
    PLoS One; 2015; 10(10):e0140585. PubMed ID: 26473951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells.
    Baran Y; Salas A; Senkal CE; Gunduz U; Bielawski J; Obeid LM; Ogretmen B
    J Biol Chem; 2007 Apr; 282(15):10922-34. PubMed ID: 17303574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.